Cara Therapeutics | CARA - Cash And Equivalent


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Cara Therapeutics

Cara Therapeutics reported $47.39M in Cash and Equivalent for its fiscal quarter ending in March of 2023.


Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 290.9M 176.05M
Cara Therapeutics CARA:US USD 47.39M 16.35M
Chugai Pharma 4519:JP JPY 247.69B 25.52B
Depomed DEPO:US USD 68.6M 3.66M
Endo International ENDP:US USD 903.61M 115.27M
Halozyme Therapeutics HALO:US USD 96.38M 137.81M
Horizon Pharma HZNP:US USD 2.31B 41.2M
J&J JNJ:US USD 3.36B 2B
Neurocrine Biosciences NBIX:US USD 103.8M 159.1M
Pacira PCRX:US USD 35.54M 68.59M
RedHill Biopharma RDHL:US USD 19.97M 4.76M
Revance Therapeutics RVNC:US USD 136.68M 27.71M
Supernus Pharmaceuticals SUPN:US USD 58.44M 34.68M
Vanda Pharmaceuticals VNDA:US USD 354.17M 219.14M